{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:41:00Z","timestamp":1760964060409,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.soc.2022.10.006","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T19:26:52Z","timestamp":1678822012000},"page":"289-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Succinate Dehydrogenase Mutations as Familial Pheochromocytoma Syndromes"],"prefix":"10.1016","volume":"32","author":[{"given":"Michael S.","family":"Lui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uriel","family":"Clemente-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Skefos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy D.","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2022.10.006_bib1","unstructured":"Pacak K, Tella SH. Pheochromocytoma and Paraganglioma. In: Feingold KR, Anawalt B, Boyce A, et\u00a0al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.Copyright \u00a9 2000-2022; 2000."},{"year":"2016","series-title":"AJCC cancer staging manual","author":"Jimenez","key":"10.1016\/j.soc.2022.10.006_bib2"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib3","doi-asserted-by":"crossref","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.soc.2022.10.006_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.soc.2022.10.006_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.soc.2022.10.006_bib7","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.1016\/j.soc.2022.10.006_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv053","article-title":"Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene","volume":"107","author":"Casc\u00f3n","year":"2015","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.soc.2022.10.006_bib9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.soc.2022.10.006_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ng.533","article-title":"Germline mutations in TMEM127 confer susceptibility to pheochromocytoma","volume":"42","author":"Qin","year":"2010","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.soc.2022.10.006_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-M\u00e9ndez","year":"2011","journal-title":"Nat Genet"},{"issue":"34","key":"10.1016\/j.soc.2022.10.006_bib12","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.soc.2022.10.006_bib13","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"17","key":"10.1016\/j.soc.2022.10.006_bib14","first-page":"5615","article-title":"Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas","volume":"63","author":"Gimenez-Roqueplo","year":"2003","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.soc.2022.10.006_bib15","doi-asserted-by":"crossref","first-page":"T91","DOI":"10.1530\/ERC-15-0268","article-title":"15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5","volume":"22","author":"Benn","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.soc.2022.10.006_bib16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/jc.2005-1862","article-title":"Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes","volume":"91","author":"Benn","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.soc.2022.10.006_bib17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations","volume":"292","author":"Neumann","year":"2004","journal-title":"Jama"},{"issue":"16","key":"10.1016\/j.soc.2022.10.006_bib18","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1001\/jama.294.16.2057","article-title":"Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene","volume":"294","author":"Schiavi","year":"2005","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1158\/1078-0432.CCR-10-0420","article-title":"SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma","volume":"17","author":"Kunst","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.soc.2022.10.006_bib20","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.soc.2022.10.006_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/humu.21136","article-title":"Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD","volume":"31","author":"Ricketts","year":"2010","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-09-0384","article-title":"Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma","volume":"161","author":"Kopetschke","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/PAS.0b013e3182671155","article-title":"Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors","volume":"37","author":"Dwight","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.soc.2022.10.006_bib24","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and\/or Pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"The J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.soc.2022.10.006_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.185","article-title":"Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas","volume":"13","author":"Toledo","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.soc.2022.10.006_bib26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/07853890.2021.1956687","article-title":"Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma","volume":"53","author":"Pipitprapat","year":"2021","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.soc.2022.10.006_bib27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/modpathol.2015.41","article-title":"SDHB\/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T)","volume":"28","author":"Papathomas","year":"2015","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.soc.2022.10.006_bib28","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","article-title":"An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis","volume":"10","author":"van Nederveen","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.soc.2022.10.006_bib29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.humpath.2009.12.005","article-title":"Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes","volume":"41","author":"Gill","year":"2010","journal-title":"Hum Pathol"},{"issue":"17","key":"10.1016\/j.soc.2022.10.006_bib30","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res : official J Am Assoc Cancer Res"},{"issue":"9","key":"10.1016\/j.soc.2022.10.006_bib31","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.soc.2022.10.006_bib32","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2265.2008.03256.x","article-title":"123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation","volume":"69","author":"Bhatia","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"10.1016\/j.soc.2022.10.006_bib34","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2967\/jnumed.108.058701","article-title":"Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial","volume":"50","author":"Wiseman","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.soc.2022.10.006_bib35","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"13","key":"10.1016\/j.soc.2022.10.006_bib36","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1245\/s10434-015-4519-y","article-title":"Hemodynamic Stability During Pheochromocytoma Resection: Lessons Learned Over the Last Two Decades","volume":"22","author":"Livingstone","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.soc.2022.10.006_bib37","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz188","article-title":"Efficacy of alpha-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial","volume":"105","author":"Buitenwerf","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.soc.2022.10.006_bib38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00268-002-6667-z","article-title":"Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma","volume":"26","author":"Prys-Roberts","year":"2002","journal-title":"World J Surg"},{"issue":"11","key":"10.1016\/j.soc.2022.10.006_bib39","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s11255-020-02539-2","article-title":"The use of doxazosin before adrenalectomy for pheochromocytoma: is the duration related to intraoperative hemodynamics and postoperative complications?","volume":"52","author":"Kong","year":"2020","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00464-020-07439-1","article-title":"Pheochromocytoma surgery without systematic preoperative pharmacological preparation: insights from a referral tertiary center experience","volume":"35","author":"Buisset","year":"2021","journal-title":"Surg Endosc"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib41","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1002\/bjs.11378","article-title":"International multicentre review of perioperative management and outcome for catecholamine-producing tumours","volume":"107","author":"Groeben","year":"2020","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.soc.2022.10.006_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archinte.1984.00350130201036","article-title":"Propranolol-induced pulmonary edema and shock in a patient with pheochromocytoma","volume":"144","author":"Sloand","year":"1984","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-198121020-00001","article-title":"alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use","volume":"21","author":"Brogden","year":"1981","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.soc.2022.10.006_bib44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez","year":"2013","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.soc.2022.10.006_bib45","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1245\/s10434-016-5739-5","article-title":"Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series","volume":"24","author":"Strajina","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.10.006_bib46","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.soc.2022.10.006_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.soc.2022.10.006_bib48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jso.23297","article-title":"Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades","volume":"107","author":"Goffredo","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib49","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00464-012-2451-9","article-title":"Outcomes of resection of extra-adrenal pheochromocytomas\/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma","volume":"27","author":"Goers","year":"2013","journal-title":"Surg Endosc"},{"issue":"1","key":"10.1016\/j.soc.2022.10.006_bib50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.surg.2017.05.025","article-title":"Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery","volume":"163","author":"Nockel","year":"2018","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2022.10.006_bib51","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.surg.2016.05.050","article-title":"SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma","volume":"161","author":"Assadipour","year":"2017","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.soc.2022.10.006_bib52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00268-013-2443-5","article-title":"Impact of surgical resection for subdiaphragmatic paragangliomas","volume":"38","author":"Abadin","year":"2014","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.soc.2022.10.006_bib53","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00268-016-3846-x","article-title":"En Bloc Resection with Major Blood Vessel Reconstruction for Locally Invasive Retroperitoneal Paragangliomas: A 15-Year Experience with Literature Review","volume":"41","author":"Hu","year":"2017","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.soc.2022.10.006_bib54","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jamcollsurg.2003.12.001","article-title":"Surgical management of hereditary pheochromocytoma","volume":"198","author":"Yip","year":"2004","journal-title":"J\u00a0Am Coll Surg"},{"issue":"2","key":"10.1016\/j.soc.2022.10.006_bib55","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jamcollsurg.2012.10.012","article-title":"Long-term outcomes of surgical treatment for hereditary pheochromocytoma","volume":"216","author":"Grubbs","year":"2013","journal-title":"J\u00a0Am Coll Surg"},{"issue":"6","key":"10.1016\/j.soc.2022.10.006_bib56","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S1470-2045(14)70154-8","article-title":"Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study","volume":"15","author":"Castinetti","year":"2014","journal-title":"The Lancet Oncol"},{"issue":"8","key":"10.1016\/j.soc.2022.10.006_bib57","doi-asserted-by":"crossref","first-page":"e198898","DOI":"10.1001\/jamanetworkopen.2019.8898","article-title":"Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy","volume":"2","author":"Neumann","year":"2019","journal-title":"JAMA Netw Open"},{"year":"2017","series-title":"AJCC cancer staging manual","author":"Amin","key":"10.1016\/j.soc.2022.10.006_bib58"},{"issue":"9","key":"10.1016\/j.soc.2022.10.006_bib59","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.soc.2022.10.006_bib60","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jamcollsurg.2013.04.027","article-title":"Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?","volume":"217","author":"Ellis","year":"2013","journal-title":"J\u00a0Am Coll Surg"},{"issue":"1","key":"10.1016\/j.soc.2022.10.006_bib61","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1530\/EJE-15-0549","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Outcome of adrenal sparing surgery in heritable pheochromocytoma","volume":"174","author":"Castinetti","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.soc.2022.10.006_bib62","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.soc.2022.10.006_bib63","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:06:24Z","timestamp":1760961984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320722000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1055320722000862"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2022.10.006","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Succinate Dehydrogenase Mutations as Familial Pheochromocytoma Syndromes","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2022.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}